Study Finds LOKELMA™ (sodium zirconium cyclosilicate) Reduces Elevated Potassium in Hemodialysis Patients

MedicalResearch.com Interview with:

Steven Fishbane MD Chief, Division of Kidney Disease and Hypertension Vice President, Northwell Health for Network Dialysis Services, Northwell Health Professor of Medicine Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Department of Medicine, Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York

Dr. Fishbane

Steven Fishbane MD
Chief, Division of Kidney Disease and Hypertension
Vice President, Northwell Health for Network Dialysis Services, Northwell Health
Professor of Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Department of Medicine, Zucker School of Medicine at Hofstra/Northwell,
Great Neck, New York 


MedicalResearch.com: What is the background for this study?

Response: Patients on hemodialysis have a great frequency of hyperkalemia. The hemodialysis treatment removes some potassium but not enough to get rid of this problem. Available medications to bind potassium have not been tested among these patients.

The purpose of the study was to see if sodium zirconium cyclosilicate could be used as a potassium binder to reduce the risk of hyperkalemia in patients on a hemodialysis.

Continue reading